Table 7.
Pre-revision, at revision, and post-revision comorbidities after OAGB/MGB
| Author/year | Number of patients | Post-revision comorbidities remission | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 year | ≤ 3 years | ≤ 5 years | |||||||||||
| HTN | T2DM | OSA | DL | HTN | T2DM | OSA | DL | HTN | T2DM | OSA | DL | ||
| AlSabah 2018 [22] | 31 | 50 | – | – | – | – | – | – | – | – | – | – | – |
| Bhandari 2019 [23] | 32 | 81.8 | 88.8 | – | – | 81.8 | 88.8 | – | – | 81.8 | 71.4 | – | – |
| Chiappetta 2019 [25] | 34 | 100 | 66.7 | 80 | 61.5 | – | – | – | – | – | – | – | – |
| Debs 2020 [26] | 77 | – | – | – | – | – | – | – | – | 65 | 62 | 82 | – |
| Jamal 2020 [30] | 56 | 42 | 40 | – | – | – | – | – | – | – | – | – | – |
| Poghosyan 2019 [27] | 72 | – | – | – | – | 21 | 75 | 70 | – | – | – | – | – |
| Musella 2019 [19] | 300 | – | – | – | – | 45 | 12 | – | 11 | – | – | – | – |
| Bruzzi 2016 [24] | 30 | – | – | – | – | – | – | – | 58 | 85 | – | 75 | |
| Chevallier 2015 [8] | 177 | – | – | – | – | 52.1 | 85.7 | 50 | 80.6 | – | – | – | – |
| Carbajo 2017 [9] | 27 | – | – | – | – | – | – | – | – | 94 | 94 | 90 | 96 |
| Poublon 2020 [31] | 185 | – | – | – | – | – | 96.9 | 87.5 | 80 | – | – | – | – |